Q1 2025 Earnings Call Transcript May 9, 2025 Operator: Greetings and welcome to the Collegium Pharmaceutical First Quarter ...

While pharmaceutical companies typically have more mature cybersecurity ... Prior to his current role, Mullen spent time both ...

Generated record quarterly net revenues of $197.1 million, representing year-over-year growth of 43.4%Total Rare Disease quarterly net revenues of $69.0 million, which includes:Purified Cortrophin® Ge ...

Angela Hwang spent nearly three decades at Pfizer before joining Flagship Pioneering in 2025 as a CEO-partner and the CEO of ...

Increased 2025 guidance with expected net revenues of $768.0 million to $793.0 million, adjusted non-GAAP EBITDA of $195.0 ...

Gyre Therapeutics ("Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biotechnology company focused on organ fibrosis, today announced financial results for the first quarter ended March 31, 2025 ...

Discover key insights from Collegium Pharmaceutical's Q1 2025 earnings call: 23% revenue growth, Jornay PM's market success, sales force expansion & ...

AbbVie’s Skyrizi took home the top spot for most pharma brand ad impressions in April 2025, according to data released by ...

M&A and IPOs got off to a quick start in 2025 only to crash into a wall of policy challenges. Upfront payment for licensing ...

Leaders from Salix Pharmaceuticals and Syneos Health Communications share their real-world journeys to becoming truly ...

Operator: Greetings and welcome to the Amphastar Pharmaceuticals First Quarter Earnings Call. At this time, all participants ...

Sales and operating profit growth, significant product acquisition completed, 11 new products, first deal outside Europe and graduation year passed January - March 2025 Consolidated sales during the ...